Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 14 chart positions in 14 markets.
By chart position
- 🇺🇸US · Life Sciences#1405K to 30K
- 🇪🇸ES · Life Sciences#3730K to 100K
- 🇰🇷KR · Life Sciences#1241K to 10K
- 🇯🇵JP · Life Sciences#1261K to 10K
- 🇳🇱NL · Life Sciences#1671K to 10K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
28K to 104K🎙 Daily cadence·69 episodes·Last published 1w ago - Monthly Reach
Unique listeners across all episodes (30 days)
92K to 346K🇪🇸29%🇩🇰29%🇺🇸9%+11 more - Active Followers
Loyal subscribers who consistently listen
37K to 138K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 10 epsHost
Recent guests
Recent episodes
Synthesizable by Design: Rethinking AI's Role in Small Molecule Drug Discovery
Jun 17, 2026
Unknown duration
From Tissue to Mechanism to Decision: Building AI for Computational Oncology
Jun 2, 2026
46m 54s
Cavities in the Data: Building FDA-Cleared AI for Dental Imaging with Overjet
May 13, 2026
58m 42s
Data as a Moat: Why Biotech's Most Valuable Asset is Buried in a Hard Drive
Apr 30, 2026
42m 52s
Markus Gershater on Why Experimental Design in Biotech is Broken and How to Fix It
Apr 15, 2026
41m 09s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/17/26 | Synthesizable by Design: Rethinking AI's Role in Small Molecule Drug Discovery | In this episode of Data in Biotech, host Ross Katz sits down with Paul Finn, Chief Scientific Officer at Oxford Drug Design, for a conversation on what it actually takes to find a drug molecule that works not just on paper but also in the lab, in the cell, and, ultimately, in the clinic. Paul brings four decades of experience across what became GSK, Pfizer, and a series of Oxford-area spinouts and has shepherded a compound all the way to a marketed drug. That perspective gives him a particular kind of skepticism toward AI results that look too good to be true because he's done the work of checking whether they are. The conversation moves through synthesizability as a first-class constraint, why chemistry has proven so much harder for AI than biology, how 3D molecular representation gets closer to the physics that actually matters, and what rigorous multi-parameter optimization looks like when you're trying to kill cancer cells and drug-resistant bacteria at the same time. What you'll learn in this episode: >> Why synthesizability is chronically underestimated and why changing a single atom in a structure can take a molecule from trivially easy to make to practically impossible >> How Oxford Drug Design constrains the generative search to reaction schemes and purchasable building blocks, and why that chemical space is still so vast that novelty is not meaningfully sacrificed >> Why most generative AI models learn from a 2D string representation of a molecule; two steps removed from the 3D physics that govern how a drug actually binds to its target >> How Bayesian optimization over reagent space, rather than molecular space, allows an active learning loop to focus on the structural patterns associated with activity >> Why benchmarking complex models against simple ones is the discipline that exposes false correlations and why Paul and his co-authors were able to recover the Halicin result using methods decades older than deep learning >> What a pharma company should actually ask an AI drug discovery vendor before buying what they're selling Meet our guest: Paul Finn is Chief Scientific Officer at Oxford Drug Design, a computational drug discovery company with roots in Oxford's chemistry department. His career spans over 40 years of computational drug discovery, from early structure-activity modeling in the 1980s through to modern generative AI methods, with deep experience at what became GSK and Pfizer before moving into the Oxford spinout ecosystem. At Oxford Drug Design, Paul leads internal programs in oncology and antibacterial resistance, combining novel computational methods with a rigorous, synthesizability-first approach to multi-parameter optimization. Connect with Paul Finn on LinkedIn: https://uk.linkedin.com/in/paul-finn-2250616 About the host: Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Ross Katz on LinkedIn: https://www.linkedin.com/in/b-ross-katz/ Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode! Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. https://www.linkedin.com/company/corrdyn/ | — | ||||||
| 6/2/26 | From Tissue to Mechanism to Decision: Building AI for Computational Oncology✨ | computational oncologybiomedical AI+4 | Arvind Rao | University of Michigan | — | AIcomputational medicine+4 | — | 46m 54s | |
| 5/13/26 | Cavities in the Data: Building FDA-Cleared AI for Dental Imaging with Overjet✨ | AI in healthcaredental imaging+4 | Sadegh Salehi | OverjetFDA | — | dental diseaseX-ray images+6 | — | 58m 42s | |
| 4/30/26 | Data as a Moat: Why Biotech's Most Valuable Asset is Buried in a Hard Drive✨ | data infrastructurebiotech+3 | Jesse Johnson | MerelogicGoogle | — | data strategybiotech labs+3 | — | 42m 52s | |
| 4/15/26 | Markus Gershater on Why Experimental Design in Biotech is Broken and How to Fix It✨ | experimental designbiotech+3 | Markus Gershater | Synthace | — | biological experimentsexperimental design automation+3 | CorrDyn | 41m 09s | |
| 4/15/26 | Data Science and Diagnostic Models - the What, Why and How with Michelle Wiest✨ | data sciencediagnostic models+3 | Michelle Wiest | FreenomeFDA | — | biostatisticsdiagnostics+5 | CorrDyn | 44m 05s | |
| 4/15/26 | The Patient is Not a Document: Foundation Models for Biomedical AI with Standard BioModel✨ | biomedical AImultimodal data+3 | Kevin Brown | Standard BioModelSiemens Healthineers+1 | — | biomedical AImultimodal foundation model+5 | — | 49m 54s | |
| 4/1/26 | Physics, Free Energy, & Drug Discovery: Inside Schrödinger's Computational Platform✨ | drug discoverycomputational modeling+4 | Robert Abel | Schrödinger | — | drug-like moleculesmachine learning+4 | — | 57m 31s | |
| 3/11/26 | AI in biotech: separating hype from reality with Ben Locwin✨ | artificial intelligencebiotechnology+4 | Ben Locwin | AlphaFoldReliant Life Sciences+1 | — | AI in biotechdata provenance+4 | — | 30m 29s | |
| 2/25/26 | 3D Printing Therapeutics at Scale with Aprecia Pharmaceuticals✨ | 3D printingpharmaceutical manufacturing+4 | Kyle SmithJacob Mayer | FDA-approved 3D printed drugAprecia Pharmaceuticals+1 | — | 3D printingpharmaceuticals+5 | — | 49m 01s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 2/11/26 | Success-Driven Drug Discovery with OpenBench CEO James Yoder✨ | drug discoverycomputational screening+3 | James Yoder | OpenBench | — | drug discoverycomputational modeling+3 | CorrDyn | 53m 37s | |
| 1/29/26 | Brant Peterson on Valo Health’s patient-first approach to drug discovery | Brant Peterson, Vice President & Fellow at Valo Health, joins Data in Biotech to explore how his team leverages real-world data, genetic insights, and machine learning to de-risk drug discovery. From building causal DAGs to identifying patient subtypes in neurodegenerative diseases like Parkinson’s, this episode dives deep into a patient-first, data-driven approach to biomedical innovation. What You'll Learn in This Episode: >> How Valo Health uses real-world evidence and EHR data to prioritize drug targets earlier in the development pipeline. >> Why integrating wet lab experiments and causal DAGs accelerates therapeutic validation. >> The importance of genetic pleiotropy and Mendelian randomization in refining disease hypotheses. >> How Valo Health identifies high-impact patient subgroups in neurodegenerative diseases like Parkinson’s and Alzheimer’s. >> Where machine learning models succeed and fall short, in uncovering mechanisms of disease from sparse longitudinal data. Meet Our Guest Brant Peterson is Vice President & Fellow in Data Science at Valo Health. He brings deep expertise in genetics, computational biology, and biomedical innovation. Formerly a Distinguished Data Scientist at Valo and Computational Biologist at Novartis, Brant focuses on leveraging patient-centric data to drive causal discovery in drug development. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Brant Peterson on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 1/14/26 | Inside Dash Bio’s productized CRO model with Ander Tallet | Ander Tallet, co-founder and COO of Dash Bio and CEO of DigitalRadius, joins Ross Katz to discuss transforming the traditional CRO model through automation, transparency, and productization. Drawing on deep experience from Moderna, Science Exchange, and his leadership roles in digital transformation, Ander shares how Dash Bio is slashing turnaround times, improving data quality, and simplifying procurement for biotech companies. This episode unpacks the future of CRO services, strategic procurement, and the power of operational innovation in biotech. What you'll learn in this episode: >> Why traditional CRO models hinder speed and transparency in biotech >> How Dash Bio delivers 90% faster turnaround through automation >> What productizing CRO services really means for the customer experience >> How regulatory requirements shape innovation in clinical bioanalysis >> Why investor buy-in requires solving real, painful problems in biotech Meet our guest Ander Tallett is the co-founder and COO of Dash Bio and the CEO of DigitalRadius, where he leads digital transformation initiatives as one of the largest Smartsheet partners in the ecosystem. He previously served as Chief Strategy Officer at Science Exchange and co-founded Block Mill Capital, a B2B SaaS-focused investment fund shaped by his experience evaluating and implementing more than 100 SaaS platforms. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with our guest: Sponsor: CorrDyn, a data consultancyConnect with Ander Tallet on LinkedIn Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 12/31/25 | From discovery to delivery: AI’s impact on nanomedicine | In this episode of Data in Biotech, Ross Katz chats with Mitra Mosharraf, Chief Scientific Officer at HTD Biosystems, about how AI and machine learning are revolutionizing nanomedicine. They explore the use of AI in drug discovery, formulation, manufacturing, and clinical development, highlighting how data-driven strategies are improving safety, reducing costs, and enabling more personalized therapies in the biotech space. What you'll learn in this episode: >> How AI and ML reduce costs and increase success rates in nanomedicine development. >> Key challenges in nano drug delivery and how machine learning helps overcome them. >> How HTD Biosystems' iFormulate platform speeds up formulation with predictive modeling. >> How wearables and real-time data are reshaping clinical trial design. >> The future of personalized and automated drug delivery systems. Meet our guest Mitra Mosharraf is the Chief Scientific Officer at HTD Biosystems and co-founder of Engimata Inc. With 20+ years of experience, she leads innovation in biologics, nanomedicine, and lipid-based delivery systems. Mitra is a recognized thought leader in pharmaceutical sciences. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Mitra Mosharraf on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 12/26/25 | Jaidev Chakka on building the future of bioprinted medicine | In this episode of Data in Biotech, Ross Katz chats with Jaidev Chakka, Principal Scientist at the University of Mississippi School of Pharmacy, about how 3D bioprinting and AI are reshaping pharmaceutical manufacturing. They explore the development of custom scaffolds for tissue engineering, the integration of gene delivery systems, and how data-driven approaches are enabling smarter, more scalable solutions in personalized medicine. What you'll learn in this episode: >> How 3D printing is enabling customized bone scaffolds and regenerative therapies >> The role of AI in optimizing pharmaceutical 3D printing parameters >> How organoids can act as micro-organs for testing and computation >> The promise and challenge of personalized, on-demand drug manufacturing >> Why collaboration between data scientists and biopharma researchers is critical Meet our guest LR Jaidev Chakka is a Principal Scientist at the University of Mississippi School of Pharmacy, pioneering 3D bioprinting, drug delivery, and organoid research to revolutionize patient care and pharma manufacturing. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Jaidev Chakka on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 12/22/25 | From screening to IND: How Veloxity accelerates critical drug decisions | In this episode of Data in Biotech, Ross Katz sits down with Callie Celichowski and Isa Kupke from Veloxity Labs to discuss how their CRO leverages speed, precision, and innovation to support drug development. Learn how they use mass spectrometry, cloud-based infrastructure, and hands-on client partnerships to drive rapid, high-quality bioanalytical insights that support everything from preclinical studies to FDA submissions. What you'll learn in this episode: >> Why "speed with purpose" is essential for bioanalytical CROs supporting biotech and pharma clients >> The benefits and challenges of working with peptides and GLP-1 receptor agonists >> How the SCIEX 8600 enhances detection of low-concentration analytes Meet our guests Isa Kupke is Scientist II at Veloxity Labs, where she specializes in mass spectrometry and method development for preclinical and regulated bioanalytical programs. She also co-founded Blyde Botanics, bridging plant-based science and product development. Callie Celichowski is Senior Director of Business Development at Veloxity Labs, with over two decades in the pharmaceutical and CRO space. She's recognized for building strategic client partnerships and driving rapid, data-driven decision-making. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Isa Kupke on LinkedIn Connect with Callie Celichowski on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 12/15/25 | Revolutionizing bioanalysis with high-resolution mass spec | In this episode of Data in Biotech, host Ross Katz sits down with Eshani Galermo, Staff Scientist at SCIEX, to explore the next generation of mass spectrometry in pharma and biopharma. Eshani explains how innovations like the ZenoTOF 8600 are redefining sensitivity, selectivity, and workflow efficiency in bioanalytical chemistry. Discover how high-resolution accurate mass (HRAM) systems are unlocking new capabilities in drug discovery, clinical studies, and regulatory science. What you'll learn in this episode: >> Why traditional mass spectrometry falls short in modern bioanalysis >> How the ZenoTOF 8600 enhances sensitivity and reduces sample volume needs >> The role of high-resolution systems in detecting complex drug metabolites >> How automation tools are streamlining workflows for bioanalytical scientists >> The complementary role of AI and ML in mass spec data analysis Meet our guest Eshani Galermo is a Staff Scientist at SCIEX, where she leads global strategic marketing initiatives for pharma and biopharma quant applications. With deep expertise in bioanalytical chemistry and mass spectrometry, she has held multiple scientific roles across SCIEX, Emery Pharma, and Genentech. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Eshani Galermo on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 12/3/25 | Mastering solubility and stability in drug development with Serán BioScience | In this episode of Data in Biotech, Ross Katz chats with Wesley Tatum, Principal Engineer at Serán BioScience, about the intricacies of formulating low-solubility drug products. They explore the science behind amorphous solid dispersions, how data informs formulation choices, and why balancing performance, manufacturability, and stability is critical in modern drug development. What you'll learn in this episode: >> How amorphous solid dispersions improve solubility and stability in drug products >> Why formulation decisions hinge on early data collection and modeling >> The role of data infrastructure in formulation R&D and knowledge transfer >> How Serán BioScience collaborates closely with clients to solve complex drug development challenges >> Where AI and automation are (and aren’t yet) transforming pharmaceutical formulation Meet our guest Wesley Tatum is a Materials Science PhD researcher working at the crossroads of materials innovation, data science, and machine learning. His work focuses on organic materials and polymer dispersions, and he’s especially passionate about how modern computational tools can transform the way we characterize and understand new materials. Wesley is well versed in PyTorch, Scikit-Learn, and a range of open-source scientific computing libraries, and he brings deep experience in chemical analysis, microscopy, and image analysis. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Wesley Tatum on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 11/26/25 | Applying ML/AI to Drug Development with Anil Kane | Dr. Anil Kane, Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, joins Ross Katz to discuss how AI, machine learning, and digital tools are reshaping drug development. From predictive modeling for formulation to digital manufacturing efficiencies, discover how data-driven approaches are reducing time, cost, and complexity in pharma innovation. What You'll Learn in This Episode: >> How predictive modeling eliminates trial-and-error in drug formulation >> The role of AI/ML in improving manufacturing efficiency and reducing downtime >> How Thermo Fisher’s ASAP program accelerates stability testing >> The future of digital transformation in pharma, including OpenAI partnerships >> Where human expertise fits in a digitally enhanced development pipeline Meet Our Guest Dr. Anil Kane is the Executive Director and Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, where he oversees a global team supporting drug development, scale-up, and technical strategy across sites in North America and Europe. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Anil Kane on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 11/20/25 | Streamlining bioanalytical workflows with Watson LIMS and Thermo Fisher | In this episode of Data in Biotech, host Ross Katz sits down with John Liberty, Senior Bioanalysis Technical Sales Consultant at Thermo Fisher Scientific. They dive deep into how Watson LIMS™ supports regulated bioanalysis workflows, the evolving role of lab automation, and how Connect Enterprise aims to unify biotech digital ecosystems. What you'll learn in this episode: >> Why Watson LIMS is purpose-built for bioanalysis and how it enhances compliance and data traceability. >> The role of lab automation in boosting productivity and reducing manual tasks. >> How Connect Enterprise integrates lab systems across vendors into a seamless workflow. >> Key considerations for implementing LIMS in startup versus established biotech environments. >> The ROI of digital lab solutions in supporting scalable, compliant biotech operations. Meet Our Guests John Liberty is a GMP-trained scientist with a strong focus on ELISA method development, validation, and transfer. He pairs his hands-on scientific background with experience in project management, CRO coordination, data analysis, and training, making him someone who really understands how work moves from the lab bench to real-world application. John has also spent time on the product and customer side, doing technical sales and demos for Watson LIMS™ software, giving him a rare blend of technical depth and communication skills. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with John Liberty on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 11/5/25 | Scaling AI infra in biotech with Saturn Cloud and Nebius | Discover how biotech and healthcare teams are fast-tracking research and development through AI and high-performance cloud infrastructure. Ross Katz sits down with Hugo Shi of Saturn Cloud and Ilya Burkov of Nebius to explore scalable, secure solutions for GPU-heavy AI workloads. From compliance to cost savings, this episode unpacks what it takes to innovate at scale in life sciences. What You'll Learn in This Episode: >> Why AI workloads in biotech demand specialized infrastructure >> How Saturn Cloud and Nebius simplify compliance, scale, and security for life sciences >> Real-world examples of gene editing, RNA sequencing, and medical imaging powered by cloud AI >> The trade-offs between hyperscalers and NeoClouds for GPU availability and cost >> Strategies for deploying, optimizing, and managing large-scale AI models Meet Our Guests Hugo Shi is the CTO and Founder of Saturn Cloud and a co-founder of Anaconda. He brings deep expertise in data science, AI infrastructure, and open-source development, helping teams scale complex workloads with minimal friction. Ilya Burkov is Global Head of Healthcare & Life Sciences Growth at Nebius. With a background in medicine and cloud technology, Ilya leads strategy and partnerships to empower biotech teams with secure, high-performance compute solutions. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Hugo Shi on LinkedIn Connect with IIya Burkov on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 10/22/25 | The Future of Co-Folding and Federated Learning with Apheris | Robin Rohm, CEO and Co-Founder of Apheris, joins Ross Katz to explore how federated learning is unlocking secure, cross-company collaboration in pharma. Discover how Apheris is enabling biopharma leaders to train cutting-edge co-folding models without sharing sensitive data, why AlphaFold 3 wasn’t enough, and what OpenFold 3 means for the future of AI in drug discovery. What You'll Learn in This Episode >> Why federated learning is a game-changer for pharma data sharing and AI-driven research >> How OpenFold 3 builds on AlphaFold’s legacy to solve the protein-ligand interaction challenge >> The role of structural benchmarking in model development and validation >> How Apheris enables privacy-preserving collaboration between major pharma players >>The importance of high-quality, proprietary datasets in advancing co-folding model accuracy Meet Our Guest Robin Rohm is the CEO and Co-Founder of Apheris, a leader in federated data networks for life sciences. With a background in mathematics and computational genomics, Robin is advancing secure AI collaboration in pharma and biotech. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Robin Roehm on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 10/1/25 | Automating biopharma knowledge work with Convoke | What if biotech teams could automate the most information-intensive parts of bringing a drug to market? In this episode of Data in Biotech, host Ross Katz speaks with Convoke co-founders Alex Telford and Maged Ahmed about building an AI-native knowledge acquisition and curation system for biopharma. Learn how they're transforming clinical research, regulatory writing, and competitive intelligence using LLMs, semantic search, and scalable data infrastructure. What You'll Learn in This Episode: >> How Convoke unifies public and private biotech data into a single workspace for smarter decision-making >> Why structured outputs and semantic layers are key to high-quality AI-driven insights >> Real-world use cases including clinical trial design, competitive landscape analysis, and regulatory documentation >> How feedback loops and model evaluations drive product reliability and user trust >> The future of AI in biotech: continuous decision-making and multimodal intelligence Meet Our Guests Alex Telford is Co-Founder and CEO of Convoke, an AI-native OS transforming drug development workflows. His background in life sciences consulting drives his mission to unify data and streamline outputs like clinical documents and regulatory submissions. Maged Ahmed is Co-Founder of Convoke and a former AI lead at Applied Intuition. He brings deep data infrastructure expertise to biotech, aiming to reduce friction in regulated environments by automating knowledge generation. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Alex Telford on LinkedIn Connect with Maged Ahmed on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 9/17/25 | How Eli Lilly’s new platform TuneLab codevelops AI models with biotech | Dr. Aliza Apple, VP of Catalyze360 AI/ML at Eli Lilly, joins Ross Katz to unveil TuneLab—a first-of-its-kind federated learning platform accelerating preclinical drug discovery. Learn how Lilly’s billion-dollar models are empowering early-stage biotechs, the science behind federated learning, and what this means for the future of pharmaceutical R&D. What You'll Learn in This Episode: >> How Eli Lilly's TuneLab democratizes access to proprietary AI models trained on decades of pharmaceutical data >> What federated learning means for IP protection and collaborative data sharing in biotech >> Which two key use cases are driving TuneLab’s impact today: small molecule ADME and antibody developability >> How TuneLab’s early adopters like Firefly Bio and Superluminal are shaping the platform’s evolution >> Why generalizability—not just accuracy—is the true power of collaborative AI in drug development Meet Our Guest Dr. Aliza Apple is VP of Catalyze360 AI/ML at Eli Lilly and a biotech trailblazer with deep roots in AI-driven drug discovery. She has led initiatives from founding startups to heading Lilly Gateway Labs and now pioneers innovation at the intersection of data and biotech. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Aliza Apple on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
| 9/3/25 | Inside Merck's Computational Biology Approach with Jesper Ryge | In this episode of Data in Biotech, host Ross Katz talks with Jesper Ryge, Director of Computational Biology at Merck Germany. Jesper shares his journey from neuroscience labs to leading computational teams, offering deep insights into disease modeling, target discovery, and multi-omics integration. Discover how AI and spatial transcriptomics are shaping the future of pharma R&D. What You'll Learn in This Episode >> How single-cell and spatial transcriptomics enhance disease mechanism discovery >> Why data integration and knowledge graphs are critical for target validation >> How computational biology teams interface with wet lab research >> What makes Merck Germany's data strategy unique in biotech >> How generative AI is changing how pharma interprets complex datasets Meet Our Guest Jesper Ryge is Director of Computational Biology at Merck Germany. A biophysicist by training, he brings deep expertise in neuroscience, single-cell analysis, and bioinformatics to pharmaceutical R&D. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about MerckConnect with Jesper Ryge on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. | — | ||||||
Showing 25 of 73
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
15 placements across 14 markets.
Chart Positions
15 placements across 14 markets.